1-9 of 9
Haiming Kou
Close
Sort by
Journal Articles

Allogeneic and Autologous Anti-CD7 CAR-T Cell Therapies in Relapsed or Refractory T Cell Malignancies

Yinqiang Zhang, Chenggong Li, Huiwen Jiang, Wenjing Luo, Mengyi Du, Fen Zhou, Lu Tang, Jianghua Wu, Qiuzhe Wei, Cong Lu, Haiming Kou, Di Wu, Chang Alex H, Heng Mei, Yu Hu
Journal: Blood
Blood (2022) 140 (Supplement 1): 4592–4594.
https://doi.org/10.1182/blood-2022-170819
Published: 2022
Journal Articles

BTK Inhibitors Improve CART19 Cell Therapy By Modulating Immune System

Wenjing Luo, Chenggong Li, Jianghua Wu, Yinqiang Zhang, Lu Tang, Mengyi Du, Xindi Wang, Wei Xiong, Haiming Kou, Cong Lu, Heng Mei, Yu Hu
Journal: Blood
Blood (2022) 140 (Supplement 1): 10294–10295.
https://doi.org/10.1182/blood-2022-170898
Published: 2022
Journal Articles

Multi-Omics Reveal Plasma Molecular Signatures of B-ALL Patients during CAR-T Cell Therapy

Jianghua Wu, Lu Tang, Mengyi Du, Chenggong Li, Haiming Kou, Huiwen Jiang, Wenjing Luo, Yinqiang Zhang, Zhongpei Huang, Danying Liao, Wei Xiong, Heng Mei, Yu Hu
Journal: Blood
Blood (2022) 140 (Supplement 1): 7384–7385.
https://doi.org/10.1182/blood-2022-166674
Published: 2022
Journal Articles

Autophagy Facilitates Cancer-Intrinsic Evasion of CAR T Cell-Mediated Cytotoxicity in B-Cell Malignancies

Heng Mei, Lu Tang, Huan Zhang, Fen Zhou, Mengyi Du, Jianghua Wu, Chenggong Li, Qiuzhe Wei, Wenjing Luo, Yinqiang Zhang, Xindi Wang, ZhaoZhao Chen, Jie Zhou, Zhuolin Wu, Zhongpei Huang, Yuxi Wen, Huiwen Jiang, Danying Liao, Haiming Kou, Yu Hu
Journal: Blood
Blood (2022) 140 (Supplement 1): 634–635.
https://doi.org/10.1182/blood-2022-168590
Published: 2022
Journal Articles

Bispecific CS1-BCMA CAR-T Cells Are Clinically Active in Relapsed or Refractory Multiple Myeloma: An Updated Clinical Study

Chenggong Li, Xindi Wang, Zhuolin Wu, Wenjing Luo, Yinqiang Zhang, Yun Kang, Jia Xu, Zhongpei Huang, Mengyi Du, Lu Tang, Jianghua Wu, Danying Liao, Haiming Kou, Cong Lu, Huiwen Jiang, Qiuzhe Wei, Sha Ke, Jing'e Zheng, Wei Xiong, Jun Deng, Yu Hu, Heng Mei
Journal: Blood
Blood (2022) 140 (Supplement 1): 4573–4574.
https://doi.org/10.1182/blood-2022-170686
Published: 2022
Journal Articles

Single-Cell Profiling Reveals Contribution of IFITM1 Expression to Severe CRS in CAR-T-Treated B-ALL

Mengyi Du, Chenggong Li, Fen Zhou, Wenjing Luo, Yinqiang Zhang, Lu Tang, Jianghua Wu, Huiwen Jiang, Qiuzhe Wei, Haiming Kou, Cong Lu, Chunrui Li, Heng Mei, Yu Hu
Journal: Blood
Blood (2022) 140 (Supplement 1): 10321–10322.
https://doi.org/10.1182/blood-2022-168695
Published: 2022
Journal Articles

Infectious Complications Following Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancy

Yingnan Li, Heng Mei, Mengyi Du, Chenggong Li, Yinqiang Zhang, Wenjing Luo, Haiming Kou, Yu Hu
Journal: Blood
Blood (2021) 138 (Supplement 1): 2831.
https://doi.org/10.1182/blood-2021-154476
Published: 2021
Journal Articles

Single-Cell Analyses Identify Transcriptional Characterizations of Subsets Associated with Efficacy and Toxicity for CAR-T Immunotherapy in B-ALL Patients

Mengyi Du, Heng Mei, Chenggong Li, Yinqiang Zhang, Lu Tang, Jianghua Wu, Haiming Kou, Yu Hu
Journal: Blood
Blood (2021) 138 (Supplement 1): 4815.
https://doi.org/10.1182/blood-2021-150216
Published: 2021
Journal Articles

Novel CD19-Specific γ/δ TCR-T Cells in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Chenggong Li, Qi Chang, Jing Wang, Mengyi Du, Lin Liu, Haiming Kou, Cong Lu, Lu Tang, Jianghua Wu, Wenjing Luo, Yinqiang Zhang, Sha Ke, Jun Deng, Cheng Liu, Yu Hu, Heng Mei
Journal: Blood
Blood (2021) 138 (Supplement 1): 826.
https://doi.org/10.1182/blood-2021-152661
Published: 2021